OrthoPediatrics (NASDAQ:KIDS) Stock Rating Upgraded by Wall Street Zen

by · The Cerbat Gem

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts also recently commented on KIDS. Lake Street Capital decreased their price target on OrthoPediatrics from $37.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, October 10th. Needham & Company LLC decreased their target price on OrthoPediatrics from $42.00 to $26.00 and set a “buy” rating for the company in a research report on Wednesday, October 29th. Weiss Ratings reissued a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Wednesday, October 8th. Truist Financial set a $18.00 price objective on shares of OrthoPediatrics in a report on Friday, October 10th. Finally, BTIG Research reissued a “buy” rating and set a $23.00 target price on shares of OrthoPediatrics in a report on Wednesday, October 29th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.00.

Get Our Latest Stock Report on OrthoPediatrics

OrthoPediatrics Stock Performance

OrthoPediatrics stock opened at $18.35 on Friday. OrthoPediatrics has a 52 week low of $15.28 and a 52 week high of $27.60. The company has a current ratio of 7.40, a quick ratio of 3.52 and a debt-to-equity ratio of 0.28. The stock has a market cap of $460.22 million, a P/E ratio of -9.41 and a beta of 1.09. The stock has a 50 day moving average of $17.86 and a 200-day moving average of $18.99.

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last posted its quarterly earnings results on Tuesday, October 28th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. OrthoPediatrics had a negative net margin of 20.06% and a negative return on equity of 6.86%. The firm had revenue of $61.25 million for the quarter, compared to analysts’ expectations of $63.63 million. On average, analysts expect that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

Hedge Funds Weigh In On OrthoPediatrics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. increased its holdings in shares of OrthoPediatrics by 433.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock worth $26,000 after acquiring an additional 1,139 shares during the period. Caption Management LLC bought a new position in OrthoPediatrics in the 3rd quarter worth about $54,000. BNP Paribas Financial Markets increased its stake in shares of OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after purchasing an additional 1,235 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of OrthoPediatrics by 6.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after buying an additional 645 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new position in shares of OrthoPediatrics during the second quarter worth approximately $220,000. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

(Get Free Report)

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.

See Also